In contrast, type 2 GBM shows overexpression or amplification of the EGFR without mutations of TP53 [11, 15], and it appears de novo, that is, in patients without a less malignant precursor neoplasm such as grade II or III astrocytoma [16]. The gene discussed is TP53; the disease is astrocytoma (excluding glioblastoma).